Early Phase 1 Hypertension Trial, Recruiting NCT05653973 Sponsor: Anna Stanhewicz, PhD Condition: Hypertension
Back to Hypertension

Early Phase 1 Hypertension Trial, Recruiting

NCT05653973
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who gave birth between 12 weeks and 5 years ago
  • People who had a normal pregnancy and did not take low-dose aspirin during that pregnancy
  • People who had a normal pregnancy and did take low-dose aspirin during that pregnancy
  • People who had preeclampsia (a pregnancy complication involving high blood pressure) and did not take low-dose aspirin during that pregnancy
  • People who had preeclampsia and did take low-dose aspirin during that pregnancy

Who may not be able to join:

  • People who currently take aspirin every day
  • People who have a skin condition or skin disease
  • People who currently use tobacco products
  • People who have been diagnosed with, or are suspected of having, a liver or metabolic disease, or a kidney disease where kidney function is significantly reduced
  • People who currently take statins or any other medication to lower cholesterol
  • People who currently take medication to lower blood pressure
  • People who had high blood pressure before their pregnancy
  • People who have a history of gestational diabetes (high blood sugar during pregnancy)
  • People who are currently pregnant
  • People whose body weight is considered underweight based on a standard height-to-weight calculation (confirm with trial site)
  • People who have an allergy to materials that may be used during the study, such as latex
  • People who have a known allergy to the study drugs

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: 319-467-1732

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Anna Stanhewicz, PhD
Registry
ClinicalTrials.gov
Start date
3 January 2023
Est. completion
31 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

microvascular endothelial function; microvascular endothelin-1-mediated constriction

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov